fda glp-1 compounding crackdown news october 2025 FDA moves to crack down

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish drugmaker Novo Nordisk that should expand access to its in-demand GLP-1 at the expense of Eli Lillys.

This can lead to gastrointestinal symptoms, malnutrition, and unintended weight loss

Start Your Weight Loss Transformation with Tirzepatide Injections in Pasadena, TX

Stomach Comfort

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.“Psoriatic arthritis seems to have a special place for increased risk for obesity,&rdquo